Orfoxen (Orforglipron) — Generic Foundayo Alternative

⚠ Important Safety Information — Read Before Continuing

Thyroid tumours (Boxed Warning): Orforglipron caused thyroid C-cell tumours in animal studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report any neck lump, hoarseness, or difficulty swallowing to your physician immediately.

Pregnancy: Weight loss during pregnancy offers no benefit and may cause fetal harm. Discontinue orforglipron immediately when pregnancy is recognised. Women using oral hormonal contraceptives must switch to a non-oral contraceptive method or add barrier contraception for 30 days after each dose initiation and each escalation step.

Prescription required: Orforglipron is a prescription-only medicine in all jurisdictions where it is approved. This site does not supply without a valid physician prescription.

Adverse events: If you experience severe abdominal pain (possible pancreatitis), a neck lump or difficulty swallowing (possible thyroid tumour), or signs of a serious allergic reaction, stop the medication and contact your physician or local emergency services immediately. Do not wait for your next scheduled appointment.

Product Overview

What Makes Orfoxen (Orforglipron) Clinically Different

Every other approved GLP-1 receptor agonist — semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro), liraglutide (Saxenda), dulaglutide (Trulicity) — is a peptide-based biologic. Peptides are broken down by stomach acid, which forces either subcutaneous injection or, for oral semaglutide, strict fasting conditions with a small water volume and a mandatory 30-minute pre-meal wait.

Orfoxen (orforglipron) is structurally different. It is a synthetic small molecule — a chemically synthesised compound that is inherently stable in the acidic gastric environment without any special formulation engineering. This single structural distinction produces five practical advantages:

1. No injection required — daily tablet with no needle or device
2. No fasting required — take with or without food, any time of day
3. No water volume restriction — no 4 oz / small-volume rule
4. No cold-chain storage — room-temperature storage, no refrigeration
5. Simpler large-scale manufacture — small-molecule synthesis, not biologic production

A dedicated food-effect pharmacokinetic study (Ma et al., Diabetes Ther, 2024) confirmed that food intake does not meaningfully alter orforglipron’s absorption or peak concentration — the scientific basis for its unrestricted administration labelling.

Approved Indications

Currently Approved — Weight Management (FDA & MHRA)

Orfoxen (orforglipron) — the Everest Pharmaceutical formulation supplied through this site — shares the same active molecule as Foundayo and is approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with:

• Obesity — BMI ≥ 30 kg/m², or
• Overweight — BMI ≥ 27 kg/m² with at least one weight-related medical condition: hypertension, dyslipidaemia, obstructive sleep apnoea, or established cardiovascular disease

Under Regulatory Review — Type 2 Diabetes

Lilly has filed regulatory submissions for orforglipron in the treatment of type 2 diabetes, supported by the Phase 3 ACHIEVE programme. As of September 2026, this indication is not yet approved. All type 2 diabetes efficacy data on this page are from clinical trials and do not reflect any current marketing authorisation.

Under Active Investigation (not approved)

• Obstructive sleep apnoea in adults with obesity
• Hypertension in adults with obesity

Note: Orforglipron must not be used concurrently with any other GLP-1 receptor agonist (semaglutide, liraglutide, tirzepatide, dulaglutide, exenatide). It has not been approved for use in patients under 18 years of age.

Phase 3 Clinical Evidence

ATTAIN-1 — Weight Management Without Diabetes (72 weeks)

ATTAIN-1 (NCT05869903) was a multinational, randomised, double-blind, placebo-controlled Phase 3 trial enrolling 3,127 adults with obesity or overweight without diabetes across nine countries. Results were published in The New England Journal of Medicine (September 2025, doi: 10.1056/NEJMoa2511774) and presented at the EASD Annual Meeting 2025.

p<0.001 for all dose-vs-placebo comparisons. All three doses met the primary and all key secondary endpoints. Approved tablet doses (0.8 mg–17.2 mg) correspond to the capsule doses used in the trial (1 mg–36 mg).

ATTAIN-2 — Weight Management With Type 2 Diabetes

ATTAIN-2 enrolled over 1,600 adults with obesity or overweight and type 2 diabetes on oral antihyperglycaemic therapy. At 72 weeks, all three doses met the primary endpoint. At the highest dose, participants achieved approximately 10% mean body weight reduction and approximately 1.8 percentage points HbA1c reduction vs placebo.

ATTAIN-MAINTAIN — Oral Switch After Injectable GLP-1 Therapy

This Phase 3b trial (Nature Medicine, 2026, doi: 10.1038/s41591-026-04386-7) enrolled adults who had previously achieved weight loss on injectable tirzepatide or semaglutide (SURMOUNT-5 participants), then randomised them to oral orforglipron or placebo for weight maintenance.

Key result: Patients switching to oral orforglipron maintained 74.7% of their previously achieved weight reduction, compared to 49.2% on placebo (estimated treatment difference 25.5%; 95% CI 14.5–36.5; p<0.001). This establishes orforglipron as a clinically validated oral maintenance option after injectable GLP-1 therapy.

ACHIEVE-3 — Head-to-Head vs Oral Semaglutide (T2D, under regulatory review)

ACHIEVE-3 (NCT06045221) enrolled 1,698 adults with type 2 diabetes inadequately controlled on metformin (baseline HbA1c 8.3%; BMI ≥25 kg/m²). Published in The Lancet (2026, doi: 10.1016/S0140-6736(26)00202-3).

ACHIEVE-4 — vs Insulin Glargine + Cardiovascular Data (T2D, under regulatory review)

ACHIEVE-4 enrolled adults with T2D, obesity or overweight, and elevated cardiovascular risk. The cardiovascular trend is reported accurately: numerically favourable but not statistically significant.

Orfoxen (Orforglipron) Dosage and Titration Schedule

Orfoxen (orforglipron) uses a structured dose-escalation schedule to minimise gastrointestinal adverse events. Each step requires a minimum of 30 days before escalation. The prescribing physician determines the appropriate maintenance dose based on individual response and tolerability — not all patients require the maximum dose.

Source: Foundayo Prescribing Information (Eli Lilly, 2026); Lilly HCP Dosing Page.

Administration Rules

• Swallow tablets whole — do not break, crush, or chew (film-coated formulation)
• Take once daily at any time — no fasting, no food restriction, no water volume requirement
• Missed dose same day: take as soon as remembered. Next day: skip and resume normal schedule. Never double-dose.
• If more than several consecutive days are missed, contact your prescriber — restart from a lower titration step may be required
• Severe gastroparesis: orforglipron is not recommended
• Oral contraceptives (important): Because orforglipron delays gastric emptying, it may reduce the absorption of oral hormonal contraceptives. Women must switch to a non-oral contraceptive method (IUD, implant, injection, patch) or add barrier contraception for 30 days after each dose initiation and 30 days after each escalation step. This applies across all six titration steps. Non-oral hormonal methods are not affected.

Orfoxen (Orforglipron) Safety Profile

Common Adverse Events — ATTAIN-1 Trial-Exact Incidence

GI adverse events are dose-dependent and most frequent during dose escalation. They typically diminish with continued therapy. Adverse-event-related discontinuation occurred in approximately 10% of participants at the highest dose. Severe GI adverse reactions were reported in approximately 3% of orforglipron-treated patients versus 1% on placebo.

⚠ If you experience severe abdominal pain, a neck lump, difficulty swallowing, or signs of a serious allergic reaction, stop the medication and contact your physician or local emergency services immediately.

Boxed Warning — Thyroid C-Cell Tumours

Orforglipron caused dose-dependent and duration-dependent thyroid C-cell adenomas and carcinomas in animal studies. Relevance to humans is not definitively established. Orforglipron is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Monitor for symptoms: neck lump or swelling, hoarseness, dysphagia, or dyspnoea.

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
• Serious hypersensitivity to orforglipron or any excipient
• Concurrent use with another GLP-1 receptor agonist
• Pregnancy — discontinue when pregnancy is recognised
• Breastfeeding — not recommended; orforglipron detected in breast milk at approximately 3× plasma concentration in animal studies

Additional Warnings

• Acute pancreatitis: Cases reported. Discontinue if confirmed; do not restart.
• Hypoglycaemia: Risk increases with insulin or insulin secretagogues; concomitant dose adjustment may be required.
• Acute gallbladder disease: Cholelithiasis and cholecystitis reported, consistent with rapid weight loss.
• Heart rate increase: Modest resting heart rate increase observed; monitor in patients with cardiac conditions.
• Severe hepatic impairment: Not recommended.
• Suicidal ideation / behaviour: Monitor in patients with history of psychiatric illness.
• Oral contraceptives: May reduce efficacy — see Dosage section above.

Hepatic Safety Note

No clinically meaningful hepatotoxicity signal (ALT, AST, ALP, bilirubin) was identified across Phase 1–3 trials. No pancreatitis, retinal, or optic neuropathy signal emerged prior to regulatory approval. Post-marketing pharmacovigilance is ongoing.

Orfoxen (Orforglipron) vs. Other GLP-1 Agents

Efficacy figures represent approximate mean weight loss at the primary trial endpoint in adults without type 2 diabetes. Individual results vary.

Orforglipron’s weight loss efficacy is numerically lower than dual-agonist tirzepatide and high-dose injectable semaglutide — a clinically honest trade-off for the convenience of a fully unrestricted once-daily oral tablet. For patients prioritising needle avoidance, ease of use, or oral maintenance after injectables (ATTAIN-MAINTAIN), orforglipron is a distinct and evidence-based option.

Access Orfoxen (Orforglipron) via Named Patient Program (NPP)

Foundayo is currently approved in the United States (April 2026) and the United Kingdom (August 2026). In countries where orforglipron has not yet received national marketing authorisation, patients may access Orfoxen (orforglipron) by Everest Pharmaceutical through Named Patient Program (NPP) or Compassionate Use frameworks, where the laws of the patient’s country permit.

What NPP Access Means

• A valid prescription from a licensed physician in the patient’s country is required before any enquiry is processed
• The prescribing physician takes full clinical responsibility for the treatment decision
• genericoncology.com acts as a pharmaceutical facilitation intermediary — not a pharmacy, not a prescriber
• Sourcing is from WHO-GMP certified manufacturers only (facility-level certification — distinct from product-level FDA approval; see disclaimer)
• The product supplied is Orfoxen (orforglipron) by Everest Pharmaceutical — a WHO-GMP certified formulation of the same active molecule, not Eli Lilly’s Foundayo branded product
• NPP eligibility and legality vary by country; our team confirms eligibility before processing any enquiry

How to Enquire — 3 Steps

1. Upload your prescription using our secure form — PDF or image format accepted
2. Our team contacts you within one business day to confirm country eligibility, stock availability, and to provide a supply quotation
3. Confirm and dispatch — once eligibility is confirmed and payment received, orders are dispatched with full WHO-GMP supply chain documentation

Frequently Asked Questoins